I believe Blue Bird shares could be near rock bottom, with potential support in the low $30s after a steep 40% selloff.

Bluebird said late Friday that Ayrmid made an unsolicited offer to buy the company in a cash-and-stock transaction with an upfront cash payment of $4.50 per share and a one-time contingent value right ...

(Reuters) -Gene therapy maker bluebird bio said on Friday it had received a non-binding offer from peer Ayrmid for up to $110.5 million, sending its shares up 9.8% at $4.40 in extended trading.

A rival bidder has emerged to acquire struggling gene therapy specialist bluebird bio. | A rival bidder has emerged to ...

Donald Campbell's Bluebird has had a new jet engine installed as part of efforts to run the record-breaking craft in the Lake ...

US gene therapy company bluebird bio (Nasdaq: BLUE) has confirmed receipt of an unsolicited non-binding written proposal from ...

The new bid surpasses an offer SK Capital and Carlyle Group made last month for the gene therapy developer, which Bluebird’s ...

In the closing of the recent trading day, Blue Bird (BLBD) stood at $34.20, denoting a -1.53% change from the preceding trading day.

We recently compiled a list of the 12 Cheap EV Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Blue Bird Corporation (NASDAQ:BLBD) stands against the ...

Bluebird conservationists discovered in the 1960s, though, that bluebirds would accept nesting boxes. But the dedicated ...

Carlyle Group's acquisition of bluebird bio for $3 per share offers a potential but unlikely $600 million sales milestone by ...

Bluebird said late Friday that Ayrmid made an unsolicited offer to buy the company in a cash-and-stock transaction with an upfront cash payment of $4.50 per share and a one-time contingent value right ...